The rat monoclonal antibody (mAb) YTH12. 5, specific for the CD3 antigen complex on
human T cells has been modified in order to improve its efficacy in human therapy. With the …

A series of hybrid‐hybridomas were derived by the cell fusion of a CD3 antibody‐secreting
hybridoma with other Ig‐producing cell lines. The Ig molecules secreted by these hybrid …

There is experimental evidence that the CD4 molecule participates in the antigen‐driven
activation of T cells expressing this surface glycoprotein. Whether CD4, a member of the …

The isotype of anti-CD3 mAb has a dramatic effect on anti-CD3 induced T-cell activation, as
was previously reported for switch variants (lgG2b to IgA) of a high-avidity IgG1 anti-CD3 …

A previously identified humanized anti-CD3 Ab variant, v9, binds T cells with> 100-fold
higher efficiency than the original variant, v1, and almost as efficiently as a chimeric …

A fully humanized anti-CD4 antibody was studied for its effects on resting and activated CD4
T cells. Whereas the antibody was poorly lytic, it induced dramatic down-modulation of CD4 …

Abstract OKT3, an anti-CD3 MAB, depletes T cells in vivo and is among the most potent
inhibitors of acute allograft rejection. The mechanism of this inhibition is unknown. The …

Murine monoclonal antibodies specifically directed at the CD3 molecular complex are
widely used in clinical transplantation. They are potent inhibitors of immune function and …

We have previously defined a panel of fully human CD20 mAb. Most of these were
unexpectedly efficient in their ability to recruit C1q to the surface of CD20-positive cells and …

Several CD4 mAbs have entered the clinic for the treatment of autoimmune diseases or
transplant rejection. Most of these mAbs caused CD4 cell depletion, and some were murine …